Accepted Manuscript

Title: Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: a National Population-Based Cohort Study

Author: Lene Sofie Granfeldt Østgård, Jennifer L. Lund, Jan Maxwell Nørgaard, Mette Nørgaard, Bruno C. Medeiros, Bendt Nielsen, Ove Juul Nielsen, Ulrik Malthe Overgaard, Maria Kallenbach, Claus Werenberg Marcher, Anders Hammerich Riis, Henrik Sengeløv

PII:	S1083-8791(17)30778-4
DOI:	https://doi.org/doi:10.1016/j.bbmt.2017.10.019
Reference:	YBBMT 54833

To appear in: Biology of Blood and Marrow Transplantation

Received date: 27-8-2017 Accepted date: 10-10-2017



Please cite this article as: Lene Sofie Granfeldt Østgård, Jennifer L. Lund, Jan Maxwell Nørgaard, Mette Nørgaard, Bruno C. Medeiros, Bendt Nielsen, Ove Juul Nielsen, Ulrik Malthe Overgaard, Maria Kallenbach, Claus Werenberg Marcher, Anders Hammerich Riis, Henrik Sengeløv, Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: a National Population-Based Cohort Study, *Biology of Blood and Marrow Transplantation* (2017), https://doi.org/doi:10.1016/j.bbmt.2017.10.019.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ØSTGÅRD et al

Regular Manuscript

Title:

Impact of allogeneic stem cell transplantation in first complete remission in acute myeloid leukemia: a national population-based cohort study

Short title:

HSCT vs. chemotherapy-only for AML in CR1

Authors:

Lene Sofie Granfeldt Østgård, MD, PhD^{1, 2}, Jennifer L. Lund, PhD^{2, 3}, Jan Maxwell Nørgaard, MD, PhD, DMCs¹, Mette Nørgaard MD, PhD², Bruno C. Medeiros, MD⁴, Bendt Nielsen, MD, DMSc¹, Ove Juul Nielsen, MD, DMSc⁵, Ulrik Malthe Overgaard, MD⁶, Maria Kallenbach, MD⁷, Claus Werenberg Marcher, MD, PhD⁸, Anders Hammerich Riis, MSc², and Henrik Sengeløv, MD, DMSc⁵

Affiliations:

¹Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; ²Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; ³Department of Epidemiology, University of North Carolina at Chapel Hill, CB #7435, Chapel Hill, NC, Unites States; ⁴ Stanford University, School of Medicine, Stanford, CA, United States; ⁵Department of Hematology, The University Hospital Rigshospitalet, Copenhagen, Denmark; ⁶Department of Hematology, Herlev University Hospital, Herlev, Denmark; ⁷Department of Hematology, Aalborg University Hospital, Aalborg, Denmark; and ⁸Department of Hematology, Odense University Hospital, Odense, Denmark

Corresponding Author:

Lene Sofie Granfeldt Østgård, MD, PhD, Department of Hematology, Aarhus University Hospital, Tage Hansens Gade 2, DK-8000 Aarhus C, Phone; +45 29728127, e-mail lenoestg@rm.dk

Financial disclosure: Aarhus University, Aarhus University Hospital, the Danish Cancer Society, the Arvid Nilsson Foundation, the Denmark-America Foundation, the Fraenkel Memorial Foundation, the Dagmar Marshall Foundation, Grocer M Brogaard and Wife Foundation, F. Ejner Willumsen's grant, the Novo Nordisk Foundation, and the Program for Clinical Research Infrastructure (PROCRIN) established by the Lundbeck Foundation.

Conflict of interest: None

Abstract: 212 Words: 2002 Tables: 2 Figures: 4 Supplementary: 4 Tables and 3 Figures References: 48

Highlight

- In a nationwide AML cohort, HSCT improves survival compared to chemotherapy-only
- The anti-leukemic effect of HSCT in CR1 reduces relapse rates and increase RFS

Download English Version:

https://daneshyari.com/en/article/8430321

Download Persian Version:

https://daneshyari.com/article/8430321

Daneshyari.com